​

​

As cancer immune therapy is rapidly gaining ground in various types of cancer, constitutively active T cell dependent auto immune attack remain as a big concern, clinically. Expressing CART proteins transiently using mRNA limits the duration of CAR-T expression. Depending on the clinical needs, mRNA stability can be adjusted via sequence engineering (e.g. optimizing the UTR sequences) or chemical modification using non-canonical nucleotides.